Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na ïve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYNOTE-01A)

Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Biological: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed;   Biological: MK-7684 Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials